Dipeptidyl-Peptidase IV Inhibitors: all 899 studies that test it
Page 7 of 9. Open to participants first (28), then studies with results posted, then the rest; newest registration first within each.
- Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229Status unknownNCT02267902Phase 1
- Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRIWithdrawnNCT02263677Phase 4
- Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney InjuryStatus unknownNCT02250872Phase 2/3
- Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical UnitWithdrawnNCT02250794Phase 4
- Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.TerminatedNCT02244164Not applicable
- DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic FibrosisStatus unknownNCT02239458Not applicable
- The Practical Evidence of Antidiabetic Combination Therapy in KoreaCompletedNCT02231021Phase 4
- Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy VolunteersCompletedNCT02221414Phase 1
- Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy VolunteersCompletedNCT02221401Phase 1
- Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy VolunteersCompletedNCT02220647Phase 1
- PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired PatientsCompletedNCT02214693Phase 1
- the Pharmacokinetic Profiles of Linagliptin With DW1029MCompletedNCT02212782Phase 1
- Correlation Between Plasma- and Endothelial DPP-4 ActivityCompletedNCT02192853Phase 4
- Effect of Gemigliptin on Metabolic Endotoxemia and LipemiaCompletedNCT02186080Not applicable
- The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male VolunteersCompletedNCT02183623Phase 1
- Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy VolunteersCompletedNCT02183584Phase 1
- Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese VolunteersCompletedNCT02183532Phase 1
- Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male VolunteersCompletedNCT02183506Phase 1
- Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female SubjectsCompletedNCT02183493Phase 1
- Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male SubjectsCompletedNCT02183467Phase 1
- Bioavailability of BI 1356 and Glyburide in Healthy Male and Female VolunteersCompletedNCT02183428Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 DiabetesCompletedNCT02183415Phase 1
- Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy VolunteersCompletedNCT02183402Phase 1
- Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male VolunteersCompletedNCT02183389Phase 1
- Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy SubjectsCompletedNCT02183376Phase 1
- Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male VolunteersCompletedNCT02183363Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 DiabetesCompletedNCT02183350Phase 1
- Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female VolunteersCompletedNCT02183337Phase 1
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183311Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male VolunteersCompletedNCT02183298Phase 1
- Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BSCompletedNCT02180503Phase 1
- Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal SubjectsCompletedNCT02175394Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male SubjectsCompletedNCT02173665Phase 1
- Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female VolunteersCompletedNCT02173652Phase 1
- Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female SubjectsCompletedNCT02173639Phase 1
- Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male VolunteersCompletedNCT02172222Phase 1
- Bioavailability of BI 10773 and Sitagliptin in Healthy Male VolunteersCompletedNCT02172196Phase 1
- A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male SubjectsCompletedNCT02163278Phase 1
- Cystic Fibrosis Related DiabetesStatus unknownNCT02148978Not applicable
- Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and HypertensionCompletedNCT02145611Phase 4
- Glycemic Durability After Metformin FailureStatus unknownNCT02142309Phase 4
- Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 DiabetesCompletedNCT02106104Phase 4
- Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes MellitusStatus unknownNCT02097342Phase 4
- Safety Evaluation of Adverse Reactions in DiabetesCompletedNCT02092597Phase 4
- DPP-4 Inhibition, Incretins and Islet FunctionCompletedNCT02089438Phase 4
- Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes MellitusTerminatedNCT02077309Phase 3
- Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)CompletedNCT02060201Phase 1
- BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.CompletedNCT02056600Phase 1
- Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical TreatmentCompletedNCT02041234Phase 4
- Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor TherapyCompletedNCT02027753Phase 4
- Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early DiabetesCompletedNCT02015299Phase 3
- Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White VolunteersCompletedNCT02004587Phase 1
- Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and MetforminCompletedNCT01990469Phase 3
- A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 DiabetesStatus unknownNCT01970046Phase 3
- Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 DiabetesStatus unknownNCT01970033Phase 3
- A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 DiabetesCompletedNCT01969357Phase 2
- Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 DiabetesCompletedNCT01969318Phase 2
- A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)CompletedNCT01968044Phase 3
- Effect of Saxagliptin on Pre-Diabetes Mellitus and ObesityStatus unknownNCT01960205Phase 4
- Linagliptin in Schizophrenia PatientsTerminatedNCT01943019Phase 1
- Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male SubjectsCompletedNCT01941199Phase 1
- A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance TestCompletedNCT01936025Phase 2
- DPP4inhibitors in Type 1 DiabetesCompletedNCT01922817Phase 3
- Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal ImpairmentCompletedNCT01903070Phase 4
- Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 DiabetesCompletedNCT01901861Not applicable
- Triple Therapy in Type 2 Diabetic PatientsStatus unknownNCT01895569Phase 4
- Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)CompletedNCT01890629Phase 4
- Diastolic Dysfunction in Patients With Type 2 Diabetes MellitusTerminatedNCT01888796Phase 3
- Bioequivalence StudyCompletedNCT01874080Phase 1
- Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 DiabetesStatus unknownNCT01867502Phase 4
- Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery DiseaseCompletedNCT01863147Phase 4
- Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II DiabetesTerminatedNCT01862263Phase 4
- MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 DiabetesCompletedNCT01847144Phase 4
- Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.CompletedNCT01835678Phase 3
- Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese WomenCompletedNCT01827280Phase 4
- Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male SubjectsCompletedNCT01825850Phase 1
- Teneligliptin(MP-513) vs. Placebo in Patient With Metformin MonotherapyCompletedNCT01805830Phase 3
- Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes MellitusCompletedNCT01798238Phase 3
- Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.dCompletedNCT01787396Phase 3
- Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male SubjectsCompletedNCT01768455Phase 1
- Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus PatientsStatus unknownNCT01768208Phase 4
- Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During RamadanCompletedNCT01758380Phase 4
- Galvus (Vildagliptin) vs Placebo in Combination With Metformin and InsulinCompletedNCT01757587Phase 4
- SYR-472 Open-label StudyCompletedNCT01751360Phase 3
- SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesCompletedNCT01744236Phase 4
- Sitagliptin in Type I Diabetic PatientsWithdrawnNCT01741103Not applicable
- Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic FibrosisCompletedNCT01721382Phase 1
- A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 DiabetesCompletedNCT01718093Phase 4
- ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate HyperglycemiaStatus unknownNCT01717911Phase 4
- Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and SaxagliptinStatus unknownNCT01703637Not applicable
- Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic VariabilityCompletedNCT01679899Phase 4
- BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered AloneCompletedNCT01662674Phase 1
- Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using "Biphase-Hyperglycemic Clamp"Status unknownNCT01660386Phase 4
- Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.CompletedNCT01649466Phase 4
- Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes MellitusStatus unknownNCT01642108Not applicable
- Double-blind Comparative Study of SYR-472CompletedNCT01632007Phase 3
- Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 DiabetesCompletedNCT01624116Not applicable
- Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763CompletedNCT01619332Phase 1/2
- Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 DiabetesCompletedNCT01617824Phase 4
- Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery DiseaseCompletedNCT01604213Phase 4